Application of co-incubation preparation of macrophage and mitochondria in promotion of ischemic myocardial repair
Through the co-incubation preparation of macrophages and primary mitochondria of myocardial myocardial primary mitochondria, macrophage metabolism reprogramming is induced, the problems of mitochondrial damage and microcirculation disorders after myocardial infarction are solved, effective repair and functional recovery after myocardial ischemia are achieved, and New treatment strategies.
Patent Information
- Application Number
- CN202411172991.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-12-03
AI Technical Summary
After myocardial infarction, although blood flow reopens the blocked coronary artery, it also causes mitochondrial damage and cardiomyocyte necrosis, and fails to resolve coronary microcirculation disorders, leading to myocardial ischemia-reperfusion injury, affecting patients for a long time Prognosis and quality of life.
By co-incubating macrophages with primary mitochondria of myocardial, macrophage metabolic reprogramming is induced, and their anti-inflammatory repair and targeting are enhanced, thereby promoting repair after myocardial ischemia.
Macrophage transplantation after mitochondria incubation can quickly replace damaged mitochondria, promote myocardial repair, reduce complications, improve cardiac function, provide new therapeutic strategies, enhance the targeting and clinical transformation value of treatment.
Smart Images

Figure CN119055756A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedicine, and in particular to an application of a co-incubation preparation of macrophages and mitochondria in promoting the repair of ischemic myocardium. Background Art
[0002] Cardiovascular disease remains one of the major social health burdens in the world today, and ischemic heart disease (IHD) is the main cause of death in these patients. In patients with myocardial infarction (MI), thrombolytic therapy and various revascularization strategies have been able to basically achieve the reopening of the blocked epicardial coronary arteries, with the goal of applying these methods within 90 minutes of clinical presentation and preferably no more than 6 hours after arterial thrombosis.
[0003] Timely reperfusion is crucial to reduce the infarct area and restore left ventricular function. It is also of great significance to the patient's long-term prognosis and quality of life. However, in clinical practice, it is found that although many patients have timely blood flow recanalization, the clinical results are still not optimistic. On the one hand, this is because reperfusion is a "double-edged sword" for myocardial infarction. While opening the blocked blood vessels, it can also cause extensive mitochondrial damage, irreversible myocardial cell necrosis and fatal ventricular arrhythmias, namely myocardial ischemia-reperfusion injury (MIRI); on the other hand, recanalization only solves the problem of blockage of the epicardial coronary arteries on the surface of the heart, but does not solve the coronary microcirculation disorder, namely the "no reflow phenomenon". Studies have shown that these phenomena account for half of the final infarct area of MI. Therefore, in addition to clinical risk scores and ventricular function assessment, long-neglected post-recanalization related issues are also potential targets for improving the long-term prognosis of IHD patients.
[0004] Currently, the effects of drug treatments for these problems are still limited: although antioxidants and drugs that inhibit calcium overload have been proven feasible in theory, there is a lack of high-quality large-scale clinical trial data; methods such as hyperbaric oxygen, hypothermia, and intermittent perfusion are promising, but clinical implementation is relatively difficult. Therefore, studying and exploring the important links and therapeutic core target interventions that occur after myocardial ischemia is the focus of preventing and alleviating IHD. Summary of the invention
[0005] To solve the above problems, the present invention co-incubates mitochondria with macrophages to induce macrophage metabolic reprogramming, enhance the effectiveness and targeting of anti-inflammatory repair, and thus improve post-myocardial ischemia repair.
[0006] After myocardial ischemia, cells in the local microenvironment will undergo temporal evolution, among which the types and transformations of macrophages are the most complex. After myocardial infarction, CCR2- myocardial in situ macrophages die, and a large number of CCR2+ cells will be recruited from circulating monocytes and evolve into local macrophages. They first play a pro-inflammatory role, remodeling the local immune microenvironment through cell fragments and releasing a large number of pro-inflammatory factors. In the later stage, phenotypic transformation occurs, activating fibroblasts to promote tissue repair, and secreting a variety of factors to promote angiogenesis. This time transition occurs about 3 days after myocardial ischemia and reaches its peak at 7 days. The occurrence and development of subsequent complications are closely related to the failure of local macrophage function to transform in time. This is mainly due to the damage of mitochondria in the cells, which cannot undergo metabolic transformation in time, thereby affecting the process of macrophage phenotypic transformation. Mitochondria are important organelles in eukaryotic cells and play an important role in energy metabolism, calcium balance, signal transduction, etc. In the early stage after myocardial infarction, mitochondrial metabolism is dominated by glycolysis, the purpose of which is to quickly generate energy to adapt to the outbreak of inflammatory response, but the interruption of TCA cycle will lead to the accumulation of inflammatory signals such as NO and ROS, at which time macrophages are mainly M1 pro-inflammatory phenotype; in the late stage, the metabolic pattern of normally functioning mitochondria will change, characterized by a complete TCA cycle and high oxidative phosphorylation rate, at which time macrophages will be reprogrammed to a pro-repair phenotype dominated by M2. It can be seen that timely metabolic reprogramming of macrophages through mitochondria is a potential intervention target for initiating early repair after myocardial infarction and alleviating complications after myocardial ischemia.
[0007] Mitochondria are organelles that must rely on intact cells to function. Traditional mitochondrial transplantation methods directly inject unmodified naked mitochondria into the blood. Although healthy mitochondria can theoretically replace or compensate for damaged mitochondria in cells and achieve certain clinical effects, their integrity, targeting and functionality have been controversial. Our research found that by incubating mitochondria with macrophages in vitro in advance, inducing their repair phenotype and then returning them to the blood, macrophages will target the ischemic myocardium and promote the improvement of cardiac function, which has stronger clinical translation value.
[0008] The specific technical solutions of the present invention are as follows:
[0009] In a first aspect, the present invention provides the use of a co-incubation preparation of macrophages and mitochondria in the preparation of a drug for promoting the repair of ischemic myocardium.
[0010] Furthermore, the macrophages are primary bone marrow macrophages, and the mitochondria are primary myocardial mitochondria.
[0011] Furthermore, the preparation method of the co-incubation preparation of macrophages and mitochondria is as follows:
[0012] Myocardial primary mitochondria were isolated and resuspended in PBS;
[0013] Primary bone marrow macrophages were extracted, resuspended in 1640 culture medium, and inoculated into a culture dish after adding MCSF; primary myocardial mitochondria were then added for co-incubation, and finally washed and resuspended in PBS to obtain a co-incubation preparation.
[0014] Furthermore, the inoculation amount of primary bone marrow macrophages is 1*10 6 / mL, the added amount of primary myocardial mitochondria was 132 μg, and the co-incubation time was 2 h.
[0015] Furthermore, the co-incubation preparation of macrophages and mitochondria is an injection preparation for intravenous injection.
[0016] In a second aspect, the present invention provides a drug for promoting ischemic myocardial repair, comprising the above-mentioned co-incubation preparation of macrophages and mitochondria.
[0017] The present invention has the following beneficial effects:
[0018] On the one hand, macrophage transplantation after mitochondrial incubation avoids the risks and uncertainties brought by simple mitochondrial transplantation, directly affects the mitochondrial function and metabolic activity of the recipient macrophages through mitochondrial transfer, and provides normal mtDNA copies, quickly replaces endogenous mtDNA, and further reproduces through replication in the recipient cells and intercellular transfer. On the other hand, early incubation of mitochondria regulates the differentiation of monocytes in the ischemic microenvironment into repair macrophages by enhancing cell metabolism, secreting cytokines related to vascular reconstruction and anti-inflammatory, which is beneficial to accelerate the process of myocardial repair after myocardial infarction. At the same time, with the help of targeted recruitment and colonization of repair macrophages to achieve targeted treatment, the extraction of autologous macrophages and intravenous reinfusion after mitochondrial incubation in vitro also has stronger clinical translation value.
[0019] In summary, mitochondria-induced macrophage metabolic reprogramming and then transplanted to promote myocardial ischemia repair can provide a new treatment strategy for patients. For clinical myocardial infarction patients, mitochondria are co-incubated with BMDM in vitro and then intravenously infused to promote myocardial ischemia repair, reduce myocardial ischemia complications and improve the quality of life of patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 : The schematic flow diagram of Example 1. In the figure:
[0021] A: Mouse bone marrow macrophages BMDM were taken and cultured with MCSF for 3 days. The Macro group was not treated, while the primary myocardial mitochondria of mice were taken from the Macro-Mito group and incubated for 2 hours, then washed and washed three times with PBS; BMDM were scraped with a cell scraper, centrifuged and counted;
[0022] B: The mouse myocardial ischemia model was implemented, and 3 days later was regarded as week 0. Mice with successful surgery were selected by echocardiography and enrolled in the group and randomly divided into MI group, MI+Macro group, and MI+Macro-Mito group. Each mouse in the MI+Macro group was injected with 200 μL of macrophage suspension without mitochondria incubation through the tail vein, and each mouse in the MI+Macro-Mito group was injected with 200 μL of macrophage suspension incubated with mitochondria through the tail vein, and the MI group was injected with an equal volume of PBS. The echocardiography data were recorded in week 1 and injected again according to the method of week 0, and the echocardiography data were recorded in week 2.
[0023] Figure 2 : Results of cardiac function evaluation after myocardial ischemia in mice treated with intravenous reinfusion of mitochondrial incubated macrophages in Example 1.
[0024] A, B, and C are the echocardiograms of mice in different groups at 0, 1, and 2 weeks, respectively; D, E, and F are the left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) of mice in different groups at 0, 1, and 2 weeks, respectively, *p<0.05, ****p<0.0001;
[0025] Sham: sham operation group, MI group: myocardial ischemia group, MI+Macro group: myocardial ischemia plus simple macrophage intravenous infusion group, MI+Macro-Mito group: myocardial ischemia plus mitochondrial pre-incubated macrophage intravenous infusion group DETAILED DESCRIPTION
[0026] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments.
[0027] Example 1
[0028] (1) Isolation of primary myocardial mitochondria: Prepare surgical instruments for autoclave sterilization, soak in alcohol, and then rinse with PBS for later use. C57BL / 6 mice of 6-8 weeks old were anesthetized with 1% amobarbital intraperitoneally and fixed on the operating table. After shaving, the skin was disinfected with alcohol. After fully exposing the chest cavity, the heart was perfused with a 10mL needle until almost no blood flowed out. The heart was completely removed and placed in an EP tube filled with PBS. The tissue was fully cut into pieces with surgical scissors, and washed three times with PBS after natural sedimentation until it was cut into very fine tissue without obvious blood stains. After adding 8 volumes of pre-cooled special pancreatic enzyme and shaking, it was incubated on ice for 20 minutes. The supernatant was discarded and 8 volumes of tissue mitochondrial isolation reagent (purchased from Biyuntian Biotechnology Co., Ltd.) were added. It was fully ground and centrifuged at 600g and 4℃ for 10 minutes. The supernatant was taken and transferred to a new EP tube. Centrifugation was continued (11000g, 10 minutes). The precipitate obtained was the primary myocardial mitochondria. The obtained mouse myocardial primary mitochondria were resuspended in PBS and counted to prepare a 0.55 mg / mL mitochondrial suspension for later use.
[0029] (2) Extraction of primary bone marrow macrophages: Prepare surgical instruments for autoclave sterilization, soak in alcohol and rinse with PBS for later use. C57BL / 6 mice of 6-8 weeks old were fixed on the operating table after intraperitoneal anesthesia with 1% amobarbital, and the skin was disinfected with alcohol after shaving. The femur and tibia of the mouse were peeled off and soaked in alcohol, washed three times with PBS, gloves and instruments were changed, the two ends of the bone were cut off, and a 1mL syringe needle and a 10mL syringe needle were combined and inserted into the bone marrow cavity and rinsed with PBS until the bone marrow cavity turned white with no obvious blood residue, and then filtered through 70μm and 40μm filters respectively, the filtrate was collected and centrifuged (1000r, 5min), the supernatant was discarded and resuspended with 1640 culture medium, and MCSF was added at 1:1000 to induce differentiation and select M0 macrophages.
[0030] (3) Construction of mouse myocardial ischemia model: Before the experiment, mice were briefly placed in an isoflurane gas anesthesia tank to induce anesthesia. During the modeling period, low-flow isoflurane was retained in the mouth and nose of the mice to maintain anesthesia. The mouse chest was depilated and disinfected with alcohol. An oblique skin incision was made along the lower edge of the left pectoralis major muscle of the mouse and toward the left upper limb of the mouse. The lower edge of the pectoralis major muscle was clamped with forceps and bluntly separated toward the left sternum. The pectoralis minor muscle can be found near the sternum. The pectoralis minor muscle was clamped and slightly separated with blunt-tipped straight forceps. The muscle was inserted from the widest part of the third intercostal space and the heart was squeezed out from the gap. The coronary artery was ligated. The needle was inserted 1 to 2 mm above the end of the bifurcation and 0.5 to 1 mm to the left. The needle was removed from the right side of the heart. The needle was inserted shallowly and removed widely to ensure that the anterior descending branch was pierced without penetrating the ventricle. A surgical ligature was tied tightly. On the third day after modeling, mice with EF values <50% were selected by echocardiography for inclusion in the group.
[0031] (4) Co-culture of mitochondria and macrophages: About 1*10 6 When the cell density reaches 80%, take 240 μL of 0.55 mg / mL mitochondrial suspension and incubate with BMDM cells for 2 h (co-incubation conditions: 37°C, 95% O 2 , 5% CO 2 ), allowing mitochondria to enter the BMDM cells, which were then washed out and washed three times with PBS.
[0032] (5) Tail vein injection of macrophages: BMDM were scraped from the culture dish, centrifuged at 1000r for 5min to separate the cells, and resuspended in 1mL PBS and counted. A mouse myocardial infarction (MI) model was constructed and divided into the Sham group (i.e., the sham operation group, which differs from the other groups in that the heart was squeezed out by making an incision beside the sternum without ligating the blood vessels and was directly returned), the MI group, the MI+Macro group, and the MI+Macro-Mito group. After homogenization, there was no statistical difference in the initial EF and FS values. Each mouse in the MI+Macro group was injected with 200μL of macrophage suspension (1*10 6 / mL), and each mouse in the MI+Macro-Mito group was injected with 200 μL of mitochondria-incubated macrophage suspension (1*10 6 / mL), and each mouse in the MI group was injected with an equal volume of PBS. Echocardiogram analysis was performed 1 week and 2 weeks after injection, including the echocardiogram manifestations and EF and FS values, which are important targets for cardiac function recovery after myocardial ischemia.
[0033] The above experimental process is as follows Figure 1 As shown in Figure 2, the results of echocardiography analysis are as follows: Figure 2 shown. Figure 2 AC shows the echocardiographic performance of the four groups of Sham, MI, MI+Macro, and MI+Macro-Mito at 0, 1, and 2 weeks. Based on the specific analysis of EF and FS values, the LVEF and LVFS of the MI group at 0 week were significantly lower than those of the Sham group, and there was no significant difference in LVEF and LVFS among the MI group, MI+Macro group, and MI+Macro-Mito group ( Figure 2 D); In the first week, the MI+Macro-Mito group increased the recovery of LVEF and LVFS compared with the MI group ( Figure 2 E); In the second week, the MI+Macro-Mito group had increased recovery of LVEF and LVFS compared with the MI group and MI+Macro group ( Figure 2 F). It can be seen that intravenous reinfusion of macrophages co-incubated with mitochondria can promote the repair of ischemic myocardium.
[0034] In summary, mitochondria regulate macrophage metabolism after transplantation, which can regulate the differentiation of monocytes in the ischemic microenvironment into repair macrophages, accelerate the repair process after myocardial ischemia, and promote angiogenesis and fibrosis. Macrophage transplantation after mitochondrial incubation has shown good therapeutic effects in the process of ischemic myocardial repair. We believe that mitochondria induce macrophages to transform into a repair phenotype through metabolic reprogramming, enhance the effectiveness and targeting of their anti-inflammatory repair, promote the remodeling of the extracellular matrix in the infarct area, and thus improve myocardial damage after infarction.
[0035] This specific implementation is only an explanation of the present invention, not a limitation of the present invention. Any changes made by those skilled in the art after reading the specification of the present invention will be protected by the patent law as long as they are within the scope of the claims of the present invention.
Claims
1. Application of co-incubation preparation of macrophages and mitochondria in the preparation of drugs for promoting the repair of ischemic myocardium.
2. The use according to claim 1, characterized in that: The macrophages are primary bone marrow macrophages, and the mitochondria are primary myocardial mitochondria.
3. The use according to claim 2, characterized in that: The preparation method of the co-incubation preparation of macrophages and mitochondria is as follows: Myocardial primary mitochondria were isolated and resuspended in PBS; Primary bone marrow macrophages were extracted, resuspended in 1640 culture medium, and inoculated into a culture dish after adding MCSF; primary myocardial mitochondria were then added for co-incubation, and finally washed and resuspended in PBS to obtain a co-incubation preparation.
4. The use according to claim 3, characterized in that: The inoculation amount of primary bone marrow macrophages is 1*10 6 / mL, the added amount of primary myocardial mitochondria was 132 μg, and the co-incubation time was 2 h.
5. The use according to claim 1, characterized in that: The co-incubation preparation of macrophages and mitochondria is an injection preparation via intravenous injection.
6. A drug for promoting the repair of ischemic myocardium, characterized in that: Preparations containing co-incubations of macrophages and mitochondria.
